University of South Alabama

 

The following Cardiology Research studies are open for enrollment.  To refer patients for any of these studies please call Cherie Revere @ 471-7916   


  ALECARDIO

ALECARDIO is a cardiovascular outcomes study designed to evaluate the potential of a dual PPAR α/γ agonist to reduce CV morbidity and mortality in patients with type 2 Diabetes, who have recently experienced an acute coronary syndrome (ACS) event.

Study Objective

The primary objective of ALECARDIO is to determine whether or not the investigational medication can reduce cardiovascular mortality and morbidity in patients with T2D, who have recently had an ACS event.

Target Population

Patients who have recently been hospitalized for an ACS event within the past 2 to 6 weeks:

  • MI with abnormal cardiac biomarkers
  • Unstable angina with no elevation of cardiac biomarkers, chest discomfort, requiring unscheduled hospital admission
  • Type 2 diabetes 

PI – Bassam Omar, MD

Study Coordinator - Cherie Revere, CRNP

For information call:  471-7916


   ATMOSPHERE

The purpose of this study is to evaluate the effect of aliskiren and aliskiren/enalapril combination therapy (compared to enalapril), on top of  conventional CHF treatment (except for ACEi that will be substituted with study treatment), in delaying time to first occurrence of either cardiovascular (CV) death or heart failure hospitalization events in patients with stable chronic heart failure (NYHA Class II- IV).

 Outpatients ≥ 18 years of age, male or female.

  • Patients with a diagnosis of chronic heart failure (NYHA Class II – IV):
  • LVEF ≤ 35% at visit 1 (local measurement, within the past 6 months assessed by echocardiography, MUGA, CT scan, MRI or ventricular angiography)
  • Elevated BNP at visit 1:
  •  BNP ≥ 150 pg/ml (according to local measurement).

                             OR

  • BNP ≥ 100 pg/ml (according to local measurement) and unplanned hospitalization for HF within the last 12 months prior to visit 1.
  • Patients must be treated with an ACE inhibitor at a stable dose (enalapril 10 mg daily at least or any other ACE inhibitor, e.g. ramipril, quinapril, lisinopril, fosinopril, perindopril, trandolapril; based on equivalent doses for at least
    4 weeks prior to visit 1.
  • Patients must be treated with a beta blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to visit 1 (for patients not on target dose, according to local guidelines, or in absence of that medication, the reason should be documented).  

PI – Clara Massey, MD

Study Coordinator - Cherie Revere, CRNP

For information call:  471-7916


 TRANSLATE-ACS

TRANSLATE-ACS: TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome

 Inclusion Criteria  (All of the following must apply)

  •  Must be 18 years
  • STEMI or NSTEMI treated with PCI
  • Treated with an ADP Receptor Inhibitor (e.g., clopidogrel, prasugrel, ticlopidine, or ticagrelor) during the MI hospitalization
  • Able to provide written information consent

 Exclusion Criteria  (None of the following can apply)

  • Patient participation in any clinical trial that specifies ADP Receptor Inhibitor treatment in the next 12 months.
  • Patient unable to comply with follow up procedures (i.e., not willing to be contacted by follow up call center) as outlined in study protocol.
  • Patient unsuitable for study participation in the estimation of the Investigator.

 Patient treatment will be at the discretion of the care team per routine clinical practice

PI – Ghulam M. Awan, MD

Study Coordinator - Cherie Revere, CRNP

For information call:  471-7916

 

Text Only Options

Change the current font size: larger | default | smaller

Current color mode is Black on White, other available modes: Yellow on Black | Black on Cream

Current color mode is Yellow on Black, other available modes: Black on White | Black on Cream

Current color mode is Black on Cream, other available modes: Black on White | Yellow on Black

Open the original version of this page.